TEMPORARY DISABLEMENT FEATURE FOR IMPLANTABLE DEVICE WITH ANTI-TACHYARRHYTHMIA FUNCTIONS

• US 20090326596A1
• Filed: 08/31/2009
• Published: 12/31/2009
• Est. Priority Date: 10/30/2003
• Status: Active Grant

• Current Assignee: Richard S. Sanders
• Original Assignee: Richard S. Sanders
• Inventors: Sanders, Richard S.
• Granted Patent: US 8,036,746 B2
• Time in Patent Office: Days
• US Class Current: 607/4
• CPC Class Codes: A61N 1/3622 comprising two or more electrodes co-operating with different heart regions
• CPC Class Codes: A61N 1/37254 Pacemaker or defibrillator security, e.g. to prevent or inhibit programming alterations by hackers or unauthorised individuals

Abstract

An implantable cardiac rhythm management device for delivering anti-tachyarrhythmia therapy is provided with a temporary disablement feature so that the delivery of anti-tachyarrhythmia therapy may be conveniently disabled and re-enabled. The feature is particularly useful to patients who are undergoing imaging procedures or surgical procedures where electro-cauterizing instruments may cause inadvertent triggering of cardioversion/defibrillation shocks and/or anti-tachycardia pacing.

Claims

1. A method for operating a cardiac device, comprising:

sensing an electrogram signal representing cardiac electrical activity and generating a chamber sense when the electrogram signal exceeds a specified threshold;

detecting a tachyarrhythmia from the rate at which chamber senses are generated;

delivering anti-tachyarrhythmia therapy through one or more stimulation channels upon detection of a tachyarrhythmia;

measuring an activity level;

disabling the delivery of anti-tachyarrhythmia therapy for a specified time interval upon receipt of a temporary suspend command from an external device via telemetry and re-enabling the delivery of anti-tachyarrhythmia therapy upon expiration of the specified time interval; and

,

re-enabling delivery of anti-tachyarrhythmia therapy before expiration of the specified time interval upon measurement of an activity level above a specified threshold value.

2. The method of claim 1 further comprising communicating the specified time interval for which the delivery of anti-tachyarrhythmia therapy is disabled to the cardiac device from the external device via telemetry.

3. The method of claim 1 further comprising re-enabling delivery of anti-tachyarrhythmia therapy before expiration of the specified time interval by receipt of a resume command from the external device via telemetry.

4. The method of claim 1 further comprising re-enabling delivery of anti-tachyarrhythmia therapy before expiration of the specified time interval upon actuation of a magnetic switch.

5. The method of claim 1 further comprising disabling the delivery of anti-tachyarrhythmia therapy indefinitely upon receipt of an indefinite suspend command from the external device via telemetry and re-enabling the delivery of anti-tachyarrhythmia therapy upon receipt of a resume command.

6. The method of claim 5 wherein the resume command is communicated to the cardiac device by actuation of the magnetic switch.

7. The method of claim 5 wherein the resume command is generated upon measurement of an activity level above a specified threshold value.

8. The method of claim 1 further comprising disabling the delivery of anti-tachyarrhythmia therapy indefinitely upon receipt of an indefinite suspend with magnetic re-enable command from the external device and re-enabling the delivery of anti-tachyarrhythmia therapy upon actuation of a magnetic switch.

9. The method of claim 1 wherein anti-tachyarrhythmia therapy is delivered in the form of anti-tachycardia pacing upon detection of a tachyarrhythmia.

10. The method of claim 1 wherein anti-tachyarrhythmia therapy is delivered in the form of a cardioversion/defibrillation shock upon detection of a tachyarrhythmia.

11. The method of claim 1 wherein anti-tachyarrhythmia therapy is delivered in the form of anti-tachycardia pacing upon detection of a tachyarrhythmia in a tachycardia zone and in the form of a cardioversion/defibrillation shock upon detection of a tachyarrhythmia in a fibrillation zone.

12. The method of claim 1 wherein anti-tachyarrhythmia therapy is disabled by disabling one or more sensing channels.

13. The method of claim 1 further comprising delivering bradycardia pacing and wherein anti-tachyarrhythmia therapy is disabled by disabling one or more sensing channels which thereby also causes the cardiac device to revert to an asynchronous pacing mode for delivery of the bradycardia pacing.

14. A method for operating a cardiac device, comprising:

sensing an electrogram signal representing cardiac electrical activity and generating a chamber sense when the electrogram signal exceeds a specified threshold;

detecting a tachyarrhythmia from the rate at which chamber senses are generated;

delivering anti-tachyarrhythmia therapy through one or more stimulation channels upon detection of a tachyarrhythmia;

disabling the delivery of anti-tachyarrhythmia therapy indefinitely upon receipt of an indefinite suspend with magnetic re-enable command from an external device via telemetry; and

,

re-enabling the delivery of anti-tachyarrhythmia therapy upon actuation of a magnetic switch.

15. The method of claim 14 further comprising delivering bradycardia pacing in an inhibited demand mode and wherein anti-tachyarrhythmia therapy is disabled by disabling a sensing channel which thereby also causes the device to revert to an asynchronous pacing mode.

16. A method for operating a cardiac device, comprising:

sensing an electrogram signal representing cardiac electrical activity and generating a chamber sense when the electrogram signal exceeds a specified threshold;

detecting a tachyarrhythmia from the rate at which chamber senses are generated;

delivering anti-tachyarrhythmia therapy through one or more stimulation channels upon detection of a tachyarrhythmia;

measuring an activity level;

disabling the delivery of the anti-tachyarrhythmia therapy indefinitely upon receipt of an indefinite suspend with activity re-enable command from an external device via telemetry; and

,

re-enabling the delivery of anti-tachyarrhythmia therapy upon measurement of an activity level above a specified threshold value.

17. The method of claim 16 further comprising delivering bradycardia pacing in an inhibited demand mode and r wherein anti-tachyarrhythmia therapy is disabled by disabling the sensing channel which thereby also causes the device to revert to an asynchronous pacing mode.

18. The method of claim 16 further comprising disabling the delivery of anti-tachyarrhythmia therapy for a specified time interval upon receipt of a temporary suspend command from the external device via telemetry and re-enabling the delivery of anti-tachyarrhythmia therapy upon expiration of the specified time interval.

19. The method of claim 16 further comprising re-enabling delivery of anti-tachyarrhythmia therapy before expiration of the specified time interval by actuation of a magnetic switch.